Audit and inspection readiness is the state of being prepared for independent review of clinical trial activities by internal auditors or regulatory authorities. Under ICH E6, sponsors should implement a quality assurance system that includes audits and be prepared for GCP inspections by bodies such as the FDA or EMA.
What Are Audits and Inspections?
An audit is a systematic and independent examination of trial-related activities and documents to determine compliance with the protocol, GCP, and applicable regulations. Audits are typically conducted by the sponsor’s Quality Assurance (QA) unit or by external auditors contracted by the sponsor. An inspection is a review conducted by a regulatory authority, such as the FDA’s Bioresearch Monitoring (BIMO) program or the EMA’s GCP inspectors, to verify compliance with regulatory requirements. Inspections can occur at investigator sites, sponsor facilities, or contract research organizations.
Regulatory Framework
ICH E6 Section 5.19 requires sponsors to conduct audits as part of their quality assurance activities and to make audit reports available to regulatory authorities upon request. The FDA and EMA have established programs for routine and for-cause GCP inspections. Inspectors evaluate compliance against 21 CFR Parts 50, 56, and 312 in the United States or the EU Clinical Trials Regulation (536/2014) in Europe.
Key Requirements
Preparation for audits and inspections requires maintaining an up-to-date and complete Trial Master File (TMF) with all essential documents readily accessible. Key records include the signed protocol, informed consent forms, adverse event reports, monitoring visit reports, and investigational product accountability logs. Staff should receive training on audit procedures and know how to interact with auditors and inspectors professionally.
Documentation
All trial documentation must be attributable, legible, contemporaneous, original, and accurate (ALCOA) to withstand scrutiny during review. The sponsor should maintain an audit trail of all quality assurance activities, including audit plans, audit reports, and corrective and preventive action (CAPA) records. Regulatory inspectors will expect to see evidence of systematic quality management and prompt resolution of identified issues.
Conclusion
Audit and inspection readiness is an ongoing requirement for all clinical trial stakeholders. Maintaining complete and accurate documentation is the most effective preparation strategy. A culture of quality and compliance throughout the trial lifecycle ensures readiness for any review.
